An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
Sponsor: Pfizer
Listed as NCT00002090, this NA trial focuses on HIV Infections and Mycobacterium Avium-Intracellulare Infection and remains completed. Sponsored by Pfizer, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States
- • Columbus, United States
- • Lackland Air Force Base, United States
- • San Antonio, United States
- • Syracuse, United States
- • The Bronx, United States